DOI QR코드

DOI QR Code

Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea

  • Lee, Dong-Gun (National Evidence-based Healthcare Collaborating Agency) ;
  • Kim, Sung-Han (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Soo-Young (National Evidence-based Healthcare Collaborating Agency) ;
  • Kim, Chung-Jong (National Evidence-based Healthcare Collaborating Agency) ;
  • Park, Wan-Beom (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Song, Young-Goo (Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Choi, Jung-Hyun (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • 발행 : 2011.06.01

초록

Neutrophils play an important role in immunological function. Neutropenic patients are vulnerable to infection, and except fever is present, inflammatory reactions are scarce in many cases. Additionally, because infections can worsen rapidly, early evaluation and treatments are especially important in febrile neutropenic patients. In cases in which febrile neutropenia is anticipated due to anticancer chemotherapy, antibiotic prophylaxis can be used, based on the risk of infection. Antifungal prophylaxis may also be considered if long-term neutropenia or mucosal damage is expected. When fever is observed in patients suspected to have neutropenia, an adequate physical examination and blood and sputum cultures should be performed. Initial antibiotics should be chosen by considering the risk of complications following the infection; if the risk is low, oral antibiotics can be used. For initial intravenous antibiotics, monotherapy with a broad-spectrum antibiotic or combination therapy with two antibiotics is recommended. At 3-5 days after beginning the initial antibiotic therapy, the condition of the patient is assessed again to determine whether the fever has subsided or symptoms have worsened. If the patient's condition has improved, intravenous antibiotics can be replaced with oral antibiotics; if the condition has deteriorated, a change of antibiotics or addition of antifungal agents should be considered. If the causative microorganism is identified, initial antimicrobial or antifungal agents should be changed accordingly. When the cause is not detected, the initial agents should continue to be used until the neutrophil count recovers.

키워드

참고문헌

  1. The Korean Society of Infectious Diseases. Infectious Disease. Seoul: Koonja Publishing Inc., 2007.
  2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751. https://doi.org/10.1086/339215
  3. Segal BH, Baden LR, Casper C, et al. NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections (v.2.2009). Fort Washington: National Comprehensive Cancer Network, 2009.
  4. Bertz H, Auner HW, Weissinger F, et al. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S167-S174.
  5. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Bohme A, Ruhnke M, et al. Treatment of invasive fungal infections in cancer patients: recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110. https://doi.org/10.1007/s00277-008-0622-5
  6. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S133-S140.
  7. Buchheidt D, Bohme A, Cornely OA, et al. Diagnosis and treatment of documented infections in neutropenic patients: recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S127-S132.
  8. Cornely OA, Bohme A, Buchheidt D, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S186-S200.
  9. Einsele H, Bertz H, Beyer J, et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S175-S185.
  10. Fatkenheuer G, Buchheidt D, Cornely OA, et al. Central venous catheter (CVC)-related infections in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S149-S157.
  11. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82 Suppl 2:S105-S117.
  12. Ruhnke M, Bohme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S141-S148.
  13. Sandherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:1051-1059. https://doi.org/10.1093/annonc/mdj132
  14. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Suppl 2007;5:32-42.
  15. Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl 2007;5:43-48.
  16. Drgona L, Paul M, Bucaneve G, Calandra T, Menichetti F. The need for aminoglycosides in combination with ${\beta}$-lactams for high-risk, febrile neutropaenic patients with leukaemia. Eur J Cancer Suppl 2007;5:13-22.
  17. Cometta A, Marchetti O, Calandra T. Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia. Eur J Cancer Suppl 2007;5:23-31.
  18. Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer Suppl 2007;5:5-12.
  19. Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005;26 Suppl 2:S128-S132.
  20. Yoshida M, Ohno R. Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 2004;39 Suppl 1:S11-S14.
  21. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004;39 Suppl 1:S65-S67.
  22. Urabe A. Clinical features of the neutropenic host: definitions and initial evaluation. Clin Infect Dis 2004;39 Suppl 1:S53-S55.
  23. Tamura K, Imajo K, Akiyama N, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004;39 Suppl 1:S15-S24.
  24. Tamura K. Initial empirical antimicrobial therapy: duration and subsequent modifications. Clin Infect Dis 2004;39 Suppl 1:S59-S64.
  25. Ohyashiki K. Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients. Clin Infect Dis 2004;39 Suppl 1:S56-S58.
  26. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004;39 Suppl 1:S49-S52.
  27. Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004;39 Suppl 1:S7-S10.
  28. The periodic health examination. Canadian task force on the periodic health examination. Can Med Assoc J 1979;121:1193-1254.
  29. Choi SM, Park SH, Lee DG, Choi JH, Yoo JH, Shin WS. Current antimicrobial usage for the management of neutropenic fever in Korea: a nationwide survey. J Korean Med Sci 2008;23:941-947. https://doi.org/10.3346/jkms.2008.23.6.941
  30. Kim HS, Song MG. Comparison of rectal temperature and tympanic membrane. Nurs Sci 1998;10(2):22-30.
  31. Fulbrook P. Core body temperature measurement: a comparison of axilla, tympanic membrane and pulmonary artery blood temperature. Intensive Crit Care Nurs 1997;13:266-272. https://doi.org/10.1016/S0964-3397(97)80425-9
  32. Dzarr AA, Kamal M, Baba AA. A comparison between infrared tympanic thermometry, oral and axilla with rectal thermometry in neutropenic adults. Eur J Oncol Nurs 2009;13:250-254. https://doi.org/10.1016/j.ejon.2009.03.006
  33. Ciuraru NB, Braunstein R, Sulkes A, Stemmer SM. The influence of mucositis on oral thermometry: when fever may not reflect infection. Clin Infect Dis 2008;46:1859-1863. https://doi.org/10.1086/588290
  34. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340. https://doi.org/10.7326/0003-4819-64-2-328
  35. Bodey GP, Rodriguez V, Chang HY, Narboni. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978;41:1610-1622. https://doi.org/10.1002/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B
  36. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715-719. https://doi.org/10.1001/archinte.1975.00330050089015
  37. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999;17:796-805.
  38. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
  39. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-2568. https://doi.org/10.1001/archinte.1988.00380120031007
  40. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.
  41. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-114.
  42. Jung JS, Kwon KY, Kim KS, et al. Risk prediction factors in febrile neutropenic patients. J Korean Soc Emerg Med 2000;11:305-315.
  43. Yoo JH, Choi SM, Lee DG, et al. Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. J Korean Med Sci 2005;20:31-35. https://doi.org/10.3346/jkms.2005.20.1.31
  44. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-995.
  45. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179-1187.
  46. Ito JI, Tegtmeier BR, O'Donnell MR. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006;354:90-94. https://doi.org/10.1056/NEJMc052613
  47. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis af ter chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-998. https://doi.org/10.1056/NEJMoa050078
  48. Bucaneve G, Micozzi A, Menichetti F, et al. Levof loxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-987. https://doi.org/10.1056/NEJMoa044097
  49. Lee DG, Choi SM, Choi JH, et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med 2002;17:38-44.
  50. Thomas X, Troncy J, Belhabri A, et al. Effectiveness of combined vancomycin and pef loxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia: a randomized double-blind study. Presse Med 2000;29:1745-1751.
  51. Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia: the Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother 1993;37:474-482. https://doi.org/10.1128/AAC.37.3.474
  52. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprof loxacin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-636. https://doi.org/10.1097/00007890-199103000-00017
  53. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987;106:1-7. https://doi.org/10.7326/0003-4819-106-1-1
  54. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients af ter chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471-5489. https://doi.org/10.1200/JCO.2007.12.3851
  55. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851. https://doi.org/10.1056/NEJM199203263261301
  56. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552. https://doi.org/10.1093/infdis/171.6.1545
  57. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of f luconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy: the Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331-340. https://doi.org/10.1086/515128
  58. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503. https://doi.org/10.7326/0003-4819-118-7-199304010-00003
  59. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-1041. https://doi.org/10.1093/infdis/172.4.1035
  60. Young GA, Bosly A, Gibbs DL, Durrant S. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia: Antifungal Prophylaxis Study Group. Eur J Cancer 1999;35:1208-1213. https://doi.org/10.1016/S0959-8049(99)00102-1
  61. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia: Multicentre Study Group. J Antimicrob Chemother 1993;31:973-984. https://doi.org/10.1093/jac/31.6.973
  62. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913-918. https://doi.org/10.7326/0003-4819-120-11-199406010-00003
  63. Annaloro C, Oriana A, Tagliaferri E, et al. Ef f icacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995;80:512-517.
  64. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999;52:376-380. https://doi.org/10.1136/jcp.52.5.376
  65. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57:317-325. https://doi.org/10.1093/jac/dki440
  66. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus f luconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-1533.
  67. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies: U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901-911. https://doi.org/10.1046/j.1365-2141.1999.01465.x
  68. Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38:127-134. https://doi.org/10.1038/sj.bmt.1705418
  69. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003;138:705-713. https://doi.org/10.7326/0003-4819-138-9-200305060-00006
  70. Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2006;29:567-586. https://doi.org/10.2165/00002018-200629070-00003
  71. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole. A broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-1617. https://doi.org/10.1086/523576
  72. Schering-Plough. Schering-Plough announces FDA approval of NOXAFIL(R) (posaconazole) for treatment of oropharyngeal candidiasis (OPC) [Internet]. PR Newswire Association, 2006 [cited 2011 May 15]. Available from: http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-23-2006/0004456852&EDATE=.
  73. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. f luconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359. https://doi.org/10.1056/NEJMoa061094
  74. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus f luconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-1416. https://doi.org/10.1086/422312
  75. Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008;88:588-595. https://doi.org/10.1007/s12185-008-0196-y
  76. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000;25:853-859. https://doi.org/10.1038/sj.bmt.1702233
  77. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-2106. https://doi.org/10.1002/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N
  78. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-582.
  79. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23:163-168. https://doi.org/10.1038/sj.bmt.1701543
  80. Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994;26:1833.
  81. Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006;17:1306-1312. https://doi.org/10.1093/annonc/mdl128
  82. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-3661.
  83. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006;8:13-20. https://doi.org/10.1111/j.1399-3062.2006.00125.x
  84. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-1408. https://doi.org/10.1086/586739
  85. Choi SM, Lee DG, Choi JH, et al. Itraconazole oral solution versus f luconazole syrup for prevention of invasive fungal infections in patients receiving hematopoietic stem cell transplantation: prospective, randomized, comparative clinical trial. Infect Chemother 2005;37:71-78.
  86. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999;28:250-255. https://doi.org/10.1086/515129
  87. Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000;30:300-305. https://doi.org/10.1086/313654
  88. Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373-378.
  89. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-514. https://doi.org/10.1016/0002-9343(94)90345-X
  90. Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 2003;9:40-45. https://doi.org/10.1007/s10156-002-0207-5
  91. Kern W, Behre G, Rudolf T, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291-301. https://doi.org/10.1002/(SICI)1097-0142(19980715)83:2<291::AID-CNCR13>3.0.CO;2-O
  92. Lass-Florl C, Gunsilius E, Gastl G, et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 2003;82:565-569. https://doi.org/10.1007/s00277-003-0666-5
  93. Van Delden C, Lew DP, Chapuis B, Rohner P, Hirschel B. Antifungal prophylaxis in severely neutropenic patients: how much fluconazole is necessary? Clin Microbiol Infect 1995;1:24-30. https://doi.org/10.1111/j.1469-0691.1995.tb00020.x
  94. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347. https://doi.org/10.1056/NEJMoa061098
  95. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627-1632. https://doi.org/10.1056/NEJM198706253162604
  96. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-1059. https://doi.org/10.4065/82.9.1052
  97. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;(3):CD005590.
  98. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:240-249. https://doi.org/10.1053/j.seminoncol.2005.12.013
  99. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24. https://doi.org/10.1086/504811
  100. Sudhoff T, Arning M, Schneider W. Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Leukemia 1997;11 Suppl 2:S38-S41.
  101. El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons: Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999;29:775-783. https://doi.org/10.1086/520433
  102. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000;6:35-43. https://doi.org/10.1016/S1083-8791(00)70050-4
  103. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999;29:1467-1471. https://doi.org/10.1086/313509
  104. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980;142:338-346. https://doi.org/10.1093/infdis/142.3.338
  105. Schubert MM, Peterson DE, Flournoy N, Meyers JD, Truelove EL. Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow transplantation: analysis of factors associated with infection. Oral Surg Oral Med Oral Pathol 1990;70:286-293. https://doi.org/10.1016/0030-4220(90)90142-F
  106. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year af ter autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001;32:391-395. https://doi.org/10.1086/318491
  107. Herrmann RP, Trent M, Cooney J, Cannell PK. Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 1999;24:1213-1217. https://doi.org/10.1038/sj.bmt.1702044
  108. Seropian S, Nadkarni R, Jillella AP, et al. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant 1999;23:599-605. https://doi.org/10.1038/sj.bmt.1701610
  109. Lee JT, Kim YT. Prevalence of antibody to herpes simplex virus. Korean J Dermatol 1993;31:38-46.
  110. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 2009;(1):CD006706.
  111. Yahav D, Gafter-Gvili A, Muchtar E, et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 2009;45:3131-3148. https://doi.org/10.1016/j.ejca.2009.08.010
  112. Liesveld JL, Abboud CN, Ifthikharuddin JJ, et al. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Transplant 2002;8:662-665. https://doi.org/10.1053/bbmt.2002.v8.abbmt080662
  113. Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 2002;36:1525-1531.
  114. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984;100:823-828. https://doi.org/10.7326/0003-4819-100-6-823
  115. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 2009;44:453-455. https://doi.org/10.1038/bmt.2009.254
  116. Choi SM, Lee DG, Park YH, et al. Infections in patients with acute leukemia: comparison of induction chemotherapy group and reinduction chemotherapy group. Infect Chemother 2003;35:78-85.
  117. Kim HB, Park SW, Kim US, et al. Infections in patients with acute leukemia (1993-1996). Korean J Hematol 1999;34:359-365.
  118. Park SH, Choi SM, Lee DG, et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci 2006;21:199-207.
  119. Rho YH, Lee YJ, Lee J, et al. Clinical aspects and prognostic factors of neutropenic fever in leukemic patients: 1996-2001. Korean J Infect Dis 2002;34:152-159.
  120. Rhee JY, Jang EH, Kim ST, et al. Profiles of infectious complications on the outcomes for the recipients of allogeneic hematopoietic stem cell transplantation. Korean J Med 2007;72:200-208.
  121. Kim JS, Oh JM. The patterns of infection and therapy in cancer patients receiving chemotherapy. J Korean Soc Health Syst Pharm 2000;17:481-500.
  122. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-311. https://doi.org/10.1056/NEJM199907293410501
  123. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral of loxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213-219. https://doi.org/10.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D
  124. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312-318. https://doi.org/10.1056/NEJM199907293410502
  125. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-231. https://doi.org/10.1016/S0002-9343(99)80367-2
  126. Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996;10:223-237. https://doi.org/10.1016/S0891-5520(05)70297-X
  127. Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 2010;18:89-94. https://doi.org/10.1007/s00520-009-0634-2
  128. Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprof loxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000;88:1710-1714. https://doi.org/10.1002/(SICI)1097-0142(20000401)88:7<1710::AID-CNCR27>3.0.CO;2-1
  129. Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprof loxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 2000;44:3264-3271. https://doi.org/10.1128/AAC.44.12.3264-3271.2000
  130. Kerr KG, Armitage HT, McWhinney PH. Activity of quinolones against viridians group streptococci isolated from blood cultures of patients with haematological malignancy. Support Care Cancer 1999;7:28-30. https://doi.org/10.1007/s005200050219
  131. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994;120:834-844. https://doi.org/10.7326/0003-4819-120-10-199405150-00004
  132. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer: the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-1115.
  133. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gramnegative infections: Antibiotic Study Group. Clin Infect Dis 1995;20:1217-1228. https://doi.org/10.1093/clinids/20.5.1217
  134. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-859. https://doi.org/10.7326/0003-4819-115-11-849
  135. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558. https://doi.org/10.1056/NEJM198608283150905
  136. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 1998;76:73-80. https://doi.org/10.1007/s002770050366
  137. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998;3:324-330.
  138. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295-1301. https://doi.org/10.1086/322646
  139. Akova M, Akan H, Korten V, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. Int J Antimicrob Agents 1999;13:15-19. https://doi.org/10.1016/S0924-8579(99)00096-5
  140. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997;41:1704-1708.
  141. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-176.
  142. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43:447-459. https://doi.org/10.1086/505393
  143. Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990;162:981-983. https://doi.org/10.1093/infdis/162.4.981
  144. Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000;18:3690-3698.
  145. Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol 2000;79:152-157. https://doi.org/10.1007/s002770050571
  146. Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, ed. Cancer Management: A Multidisciplinary Approach. 12th ed. Manhasset, NY: CMP Medica, 2009.
  147. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338-348. https://doi.org/10.1016/S1473-3099(07)70109-3
  148. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176-189. https://doi.org/10.1093/jac/dki448
  149. Jung HW, Chae JW, Kang MR, et al. Comparative efficacy and safety of cefepime alone versus ceftazidime plus tobramycin in cancer patients with febrile neutropenia. Infect Chemother 2004;36:341-349.
  150. Lee DH, Kim CK, Ko JY, et al. A comparative study of cefepime versus ceftazidime monotherapy as empirical therapy for febrile episodes in neutropenic patients. J Korean Soc Chemother 2002;20:243-251.
  151. Flaherty JP, Waitley D, Edlin B, et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 1989;87(5A):278S-282S.
  152. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer: the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995;39:445-452. https://doi.org/10.1128/AAC.39.2.445
  153. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis 1997;24:41-51. https://doi.org/10.1093/clinids/24.1.41
  154. Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients: a randomized, double-blind trial. Ann Intern Med 2002;137:77-87. https://doi.org/10.7326/0003-4819-137-2-200207160-00005
  155. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002;50:79-88. https://doi.org/10.1093/jac/dkf087
  156. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-1555.
  157. Torfoss D, Hoiby EA, Tangen JM, et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother 2007;59:711-717. https://doi.org/10.1093/jac/dkm003
  158. Choi SM, Lee DG, Kim MJ, et al. Clinical features and risk factors of the septic shock in patients with neutropenic fever. Infect Chemother 2003;35:370-376.
  159. Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 2000;18:3699-3706.
  160. Kim WS, Lee H, Ki HK, et al. The efficacy and safety of oral ciprofloxacin therapy for low-risk febrite patients with neutropenia during cancer chemotherapy. J Korean Soc Chemother 2000;18:29-38.
  161. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991;163:951-958. https://doi.org/10.1093/infdis/163.5.951
  162. Micozzi A, Venditti M, Amadori S, Pulsoni A, Tirindelli C, Martino P. Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients. Br J Haematol 1990;76 Suppl 2:19-23.
  163. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:431-439. https://doi.org/10.1016/S1473-3099(05)70164-X
  164. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005;55:436-444. https://doi.org/10.1093/jac/dki028
  165. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-259. https://doi.org/10.1086/514550
  166. Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IG, Prentice A. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11 Suppl 5:17-23.
  167. Kim SH, Park WB, Lee KD, et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004;54:489-497. https://doi.org/10.1093/jac/dkh366
  168. Uh Y, Hwang GY, Jang IH, Kwon O, Kim HY, Yoon KJ. Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic viridians group streptococci in a tertiary Korean hospital. J Korean Med Sci 2007;22:791-794. https://doi.org/10.3346/jkms.2007.22.5.791
  169. Uh Y, Hwang GY, Jang IH, Yoon KJ, Kim HY. Antimicrobial susceptibilities of viridans streptococci isolated from blood cultures during recent period. J Lab Med Qual Assur 2002;24:225-230.
  170. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382-389. https://doi.org/10.1086/376637
  171. Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000;45:843-849. https://doi.org/10.1093/jac/45.6.843
  172. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53:4069-4079. https://doi.org/10.1128/AAC.00341-09
  173. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. https://doi.org/10.1086/524667
  174. Brink AJ, Richards GA, Cummins RR, Lambson J; Gauteng Understanding Teicoplanin Serum levels (GUTS) study group. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008;32:455-458. https://doi.org/10.1016/j.ijantimicag.2008.05.012
  175. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 1984;63:189-200.
  176. Cercenado E, Ena J, Rodriguez-Creixems M, Romero I, Bouza E. A conservative procedure for the diagnosis of catheter-related infections. Arch Intern Med 1990;150:1417-1420. https://doi.org/10.1001/archinte.1990.00390190077011
  177. Blot F, Nitenberg G, Chachaty E, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 1999;354:1071-1077. https://doi.org/10.1016/S0140-6736(98)11134-0
  178. Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004;140:18-25. https://doi.org/10.7326/0003-4819-140-1-200401060-00007
  179. Krause R, Auner HW, Gorkiewicz G, et al. Detection of catheter-related bloodstream infections by the differential-time-to-positivity method and gram stain-acridine orange leukocyte cytospin test in neutropenic patients after hematopoietic stem cell transplantation. J Clin Microbiol 2004;42:4835-4837. https://doi.org/10.1128/JCM.42.10.4835-4837.2004
  180. Abdelkefi A, Achour W, Ben Othman T, et al. Difference in time to positivity is useful for the diagnosis of catheter-related bloodstream infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35:397-401. https://doi.org/10.1038/sj.bmt.1704773
  181. Blot F, Schmidt E, Nitenberg G, et al. Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol 1998;36:105-109.
  182. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Updateby the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45. https://doi.org/10.1086/599376
  183. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48:203-212. https://doi.org/10.1086/595686
  184. Kim SH, Kang CI, Kim HB, et al. Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003;24:897-904. https://doi.org/10.1086/502157
  185. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990;89:137-141. https://doi.org/10.1016/0002-9343(90)90290-T
  186. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-111. https://doi.org/10.1016/0002-9343(82)90594-0
  187. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989;86:668-672. https://doi.org/10.1016/0002-9343(89)90441-5
  188. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 2004;23:105-112. https://doi.org/10.1016/j.ijantimicag.2003.11.002
  189. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004;39 Suppl 1:S38-S43.
  190. Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer 2008;44:2192-2203. https://doi.org/10.1016/j.ejca.2008.06.040
  191. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176-1184. https://doi.org/10.1086/592255
  192. Yoo JH, Choi JH, Lee DG, Choi S, Shin WS, Kim CC. Analysis of invasive fungal infection after hematopoietic stem cell transplantation or chemotherapy in patients with hematologic diseases. Infect Chemother 2004;36:40-45.
  193. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360. https://doi.org/10.1086/525258
  194. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535. https://doi.org/10.1086/596757
  195. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27:3398-3409. https://doi.org/10.1200/JCO.2008.20.1178
  196. Lee JS, Shin JH, Lee K, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007;48:779-786. https://doi.org/10.3349/ymj.2007.48.5.779
  197. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. Int J Antimicrob Agents 2007;29:501-509. https://doi.org/10.1016/j.ijantimicag.2006.11.026
  198. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771. https://doi.org/10.1056/NEJM199903113401004
  199. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234. https://doi.org/10.1056/NEJM200201243460403
  200. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-1402. https://doi.org/10.1056/NEJMoa040446
  201. Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009;49:1226-1236. https://doi.org/10.1086/605665
  202. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718. https://doi.org/10.1046/j.1365-2141.1997.2473063.x
  203. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001;135:412-422. https://doi.org/10.7326/0003-4819-135-6-200109180-00010
  204. Park SH, Choi SM, Lee DG, et al. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. Korean J Intern Med 2006;21:165-172.
  205. Schuler U, Bammer S, Aulitzky WE, et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 2007;30:185-191. https://doi.org/10.1159/000100055
  206. Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-1884. https://doi.org/10.1056/NEJMra0808853
  207. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-289. https://doi.org/10.1016/S0002-9343(99)00457-X
  208. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821. https://doi.org/10.1086/588660
  209. Ben-Ami R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 2009;22:376-384. https://doi.org/10.1097/QCO.0b013e32832db9f3
  210. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-1250. https://doi.org/10.1086/496927
  211. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preempt ive ant ifungal therapy for high-r isk, febr ile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-1051. https://doi.org/10.1086/597395
  212. Yoo JH, Choi JH, Choi SM, et al. Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases. Clin Infect Dis 2005;40:392-398. https://doi.org/10.1086/427284
  213. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006;20:711-727. https://doi.org/10.1016/j.idc.2006.06.009
  214. Song KH, Lee S, Jang HC, et al. Diagnostic usefulness of galactomannan assay for invasive aspergillosis. Infect Chemother 2009;41:82-89. https://doi.org/10.3947/ic.2009.41.2.82
  215. O'Shaughnessy EM, Shea YM, Witebsky FG. Laboratory diagnosis of invasive mycoses. Infect Dis Clin North Am 2003;17:135-158. https://doi.org/10.1016/S0891-5520(02)00069-7
  216. Pfeif fer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-1427. https://doi.org/10.1086/503427
  217. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009;47:129-133. https://doi.org/10.1128/JCM.00506-08
  218. Yoo JH, Choi SM, Lee DG, et al. Comparison of the real-time nucleic acid sequence-based amplification (RTi-NASBA) with conventional NASBA, and galactomannan assay for the diagnosis of invasive aspergillosis. J Korean Med Sci 2007;22:672-676. https://doi.org/10.3346/jkms.2007.22.4.672

피인용 문헌

  1. Tool for Guidance: Evidence-Based Recommendations for Managing Febrile Neutropenia vol.26, pp.2, 2011, https://doi.org/10.3904/kjim.2011.26.2.135
  2. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational stu vol.67, pp.6, 2011, https://doi.org/10.1093/jac/dks043
  3. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases vol.18, pp.suppl7, 2012, https://doi.org/10.1111/1469-0691.12037
  4. Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma vol.27, pp.12, 2012, https://doi.org/10.3346/jkms.2012.27.12.1468
  5. Clinical Practice Guidelines for Soft Tissue Infections vol.44, pp.4, 2012, https://doi.org/10.3947/ic.2012.44.4.213
  6. Overview of Antibiotic Use in Korea vol.44, pp.4, 2012, https://doi.org/10.3947/ic.2012.44.4.250
  7. A Case of Disseminated Candidiasis and Subsequent Breakthrough Pulmonary Mucormycosis after Consolidation Chemotherapy for Acute Myeloid Leukemia vol.44, pp.6, 2011, https://doi.org/10.3947/ic.2012.44.6.544
  8. Comparison of the QuantiFERON‐TB Gold In‐Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation vol.15, pp.1, 2013, https://doi.org/10.1111/j.1399-3062.2012.00765.x
  9. Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and c vol.13, pp.None, 2011, https://doi.org/10.1186/1471-2334-13-273
  10. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study vol.13, pp.None, 2011, https://doi.org/10.1186/1471-2334-13-504
  11. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies vol.51, pp.3, 2011, https://doi.org/10.3109/13693786.2012.694082
  12. Posaconazole Treatment in Korea: Single-Center Experience Over 5 Years vol.54, pp.5, 2011, https://doi.org/10.3349/ymj.2013.54.5.1234
  13. Common Infectious Diseases in Hematopoietic Stem Cell Transplant Recipients vol.84, pp.2, 2011, https://doi.org/10.3904/kjm.2013.84.2.158
  14. Infection Prevention in Transplant Recipients vol.84, pp.2, 2011, https://doi.org/10.3904/kjm.2013.84.2.168
  15. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome vol.92, pp.4, 2011, https://doi.org/10.1007/s00277-012-1631-y
  16. Epidemiology and Clinical Features of Bloodstream Infections in Hematology Wards: One Year Experience at the Catholic Blood and Marrow Transplantation Center vol.45, pp.1, 2011, https://doi.org/10.3947/ic.2013.45.1.51
  17. A Population-Based Study of Bacterial Spectrum in Febrile Neutropenic Patients vol.6, pp.2, 2013, https://doi.org/10.5812/jjm.4941
  18. Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia vol.41, pp.5, 2013, https://doi.org/10.1007/s15010-013-0470-7
  19. T-SPOT.TB for Detection of Tuberculosis Infection among Hematological Malignancy Patients and Hematopoietic Stem Cell Transplant Recipients vol.14, pp.12, 2011, https://doi.org/10.7314/apjcp.2013.14.12.7415
  20. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients vol.93, pp.1, 2011, https://doi.org/10.1007/s00277-013-1826-x
  21. Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in vol.29, pp.1, 2014, https://doi.org/10.3346/jkms.2014.29.1.61
  22. Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP vol.29, pp.11, 2011, https://doi.org/10.3346/jkms.2014.29.11.1493
  23. Clinical Outcomes and Prognostic Factors of Empirical Antifungal Therapy with Itraconazole in the Patients with Hematological Malignancies: A Prospective Multicenter Observational Study in Korea vol.55, pp.1, 2011, https://doi.org/10.3349/ymj.2014.55.1.9
  24. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations vol.15, pp.None, 2011, https://doi.org/10.1186/s12879-015-0801-7
  25. Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis vol.15, pp.None, 2011, https://doi.org/10.1186/s12879-015-1014-9
  26. Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia vol.56, pp.1, 2011, https://doi.org/10.3109/10428194.2014.911864
  27. Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single-center experience vol.17, pp.1, 2011, https://doi.org/10.1111/tid.12341
  28. Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Bacteremia in Febrile Neutropenic Children vol.21, pp.2, 2015, https://doi.org/10.1089/mdr.2014.0092
  29. Invasive Pulmonary Aspergillosis-mimicking Tuberculosis vol.61, pp.1, 2011, https://doi.org/10.1093/cid/civ216
  30. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single‐centre retrospective study vol.58, pp.9, 2015, https://doi.org/10.1111/myc.12357
  31. A new prognostic model for chemotherapy-induced febrile neutropenia vol.21, pp.1, 2011, https://doi.org/10.1007/s10147-015-0853-0
  32. Collaborative Pharmacokinetic–Pharmacodynamic Research for Optimization of Antimicrobial Therapy vol.48, pp.3, 2011, https://doi.org/10.3947/ic.2016.48.3.254
  33. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field vol.14, pp.12, 2011, https://doi.org/10.1080/14787210.2016.1245613
  34. Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases : Comparison between Aspergillus fumigatus and non- fumigatus Aspergillus species vol.96, pp.49, 2011, https://doi.org/10.1097/md.0000000000008841
  35. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population vol.12, pp.3, 2011, https://doi.org/10.1371/journal.pone.0173250
  36. Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study vol.55, pp.3, 2011, https://doi.org/10.1093/mmy/myw067
  37. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation vol.15, pp.5, 2017, https://doi.org/10.1080/14787210.2017.1305886
  38. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study vol.17, pp.None, 2017, https://doi.org/10.1186/s12879-017-2597-0
  39. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea vol.33, pp.2, 2011, https://doi.org/10.3904/kjim.2018.036
  40. Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents vol.56, pp.2, 2011, https://doi.org/10.1093/mmy/myx038
  41. Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use: a quasi-experimental study in a region of high MRSA prevalence vol.18, pp.None, 2018, https://doi.org/10.1186/s12879-018-3081-1
  42. Comparison of Enterococcus faecium Bacteremic Isolates from Hematologic and Non-hematologic Patients: Differences in Antimicrobial Resistance and Molecular Characteristics vol.38, pp.3, 2018, https://doi.org/10.3343/alm.2018.38.3.226
  43. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations vol.40, pp.3, 2011, https://doi.org/10.1097/ftd.0000000000000498
  44. Clinical characteristics and drug tolerance for Pseudomonas aeruginosa infection in patients with agranulocytosis and fever in Shanghai vol.17, pp.None, 2011, https://doi.org/10.1177/2058739218824946
  45. Correlation of fungal cultures from non-sterile sites and Galactomannan assay with the diagnosis of aspergillosis and mucormycosis based on sterile culture results and histopathologic findings vol.51, pp.5, 2011, https://doi.org/10.1080/23744235.2019.1590632
  46. Enterococcal bacteremia in febrile neutropenic children and adolescents with underlying malignancies, and clinical impact of vancomycin resistance vol.47, pp.3, 2011, https://doi.org/10.1007/s15010-018-1260-z
  47. Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance vol.35, pp.4, 2020, https://doi.org/10.3904/kjim.2018.306
  48. Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies vol.26, pp.1, 2011, https://doi.org/10.1080/16078454.2021.1872957
  49. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis vol.11, pp.1, 2011, https://doi.org/10.1038/s41598-021-01716-2
  50. Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis vol.13, pp.24, 2011, https://doi.org/10.3390/cancers13246285